Lorlatinib
WHO Grade III Glioma
Nationwide Children's HospitalSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the WHO Grade III Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Virginia Commonwealth University | Phase 2 | BB |
Everolimus Nationwide Children's Hospital | Phase 2 | B |
Fycompa Mayo Clinic | Phase 4 | B |
Pamiparib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | B |
Capecitabine M.D. Anderson Cancer Center | Phase 2 | B |
View all 38 →
Same molecule, other indications
Lorlatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →